VivoSim Labs Announces $4M Public Offering Pricing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy VIVS?
Source: seekingalpha
- Offering Size: VivoSim Labs announced a best-efforts public offering of up to $4 million, with an initial closing expected to raise $3 million on April 1, 2026, indicating the company's intent to leverage capital markets for growth.
- Stock Issuance Details: The initial closing will involve the issuance of 286,557 common shares at a subscription price of $1.140 per share, along with 2.34 million prefunded warrants, showcasing the company's flexible financing structure.
- Warrant Arrangement: The company will issue 3.95 million common warrants allowing the purchase of up to 150% of the common stock sold, with an exercise price of $1.710 per share, immediately exercisable and expiring in five years, enhancing potential returns for investors.
- Subsequent Financing Plans: The second closing will consist of an additional $1 million in common stock or prefunded warrants, subject to conditions like minimum closing price and average trading volume, reflecting the company's sensitivity to market dynamics and cautious financing strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VIVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VIVS
About VIVS
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The Company offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. It uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The Company's 3D human tissue platform is multifaceted. The Company has expertise in 3D organoids, such as spheroids, and has made advances in proprietary cell culture techniques including ratios, components and conditions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VivoSim Labs Announces $4M Public Offering Pricing
- Offering Size: VivoSim Labs announced a best-efforts public offering of up to $4 million, with an initial closing expected to raise $3 million on April 1, 2026, indicating the company's intent to leverage capital markets for growth.
- Stock Issuance Details: The initial closing will involve the issuance of 286,557 common shares at a subscription price of $1.140 per share, along with 2.34 million prefunded warrants, showcasing the company's flexible financing structure.
- Warrant Arrangement: The company will issue 3.95 million common warrants allowing the purchase of up to 150% of the common stock sold, with an exercise price of $1.710 per share, immediately exercisable and expiring in five years, enhancing potential returns for investors.
- Subsequent Financing Plans: The second closing will consist of an additional $1 million in common stock or prefunded warrants, subject to conditions like minimum closing price and average trading volume, reflecting the company's sensitivity to market dynamics and cautious financing strategy.
See More
VivoSim Plans Up to $4M Best-Efforts Public Offering
- Offering Overview: VivoSim (VIVS) plans a best-efforts public offering of up to $4 million in common stock or pre-funded warrants, along with warrants tied to an additional $15 million in shares, indicating the company's proactive approach to capital markets.
- Unit Structure Details: Each unit consists of a share or pre-funded warrant and a warrant to purchase 1.5 shares, priced at an assumed $1.69 per unit, designed to attract more investor participation in the offering.
- Anti-Dilution Protection: Common warrants are immediately exercisable, expire in five years, and include anti-dilution price protection with a $0.01 floor, providing additional security for investors and enhancing the offering's appeal.
- Phased Offering Strategy: The financing is structured in two tranches: an initial $3 million and a second tranche of $1 million, subject to stock price and liquidity conditions, demonstrating the company's sensitivity to market dynamics and ability to adapt accordingly.
See More
VivoSim Labs Expands NAMKind Services to Asia-Pacific Region
- Market Expansion: VivoSim Labs has signed agreements with JCBio and Tekon Biotech as authorized distributors for NAMKind services in Korea and China, significantly enhancing its commercial presence in the Asia-Pacific region and expected to drive market share growth in rapidly expanding markets.
- Service Innovation: The NAMKind human-based toxicology services are designed to help drug developers identify liver and gastrointestinal liabilities earlier, thereby reducing the likelihood of downstream failures and providing pharmaceutical and biotechnology companies with more efficient asset prioritization.
- Growing Demand: The company is scaling capacity to meet increasing global demand, particularly as drug developers seek earlier readouts and clearer translation to clinical outcomes, which will help reduce late-stage attrition rates.
- Sentiment Shift: Over the past 24 hours, retail sentiment around VIVS stock on Stocktwits shifted from 'bearish' to 'extremely bullish', with message volume increasing from 'normal' to 'extremely high', indicating strong investor confidence in the company's future performance.
See More
U.S. Stocks Decline in Morning Trading, Dow Jones Drops Over 100 Points
- Market Performance: U.S. stocks traded lower this morning, with the Dow Jones index dropping over 100 points, reflecting a 0.28% decline to 48,933.32, indicating weakened market sentiment that could impact investor confidence.
- Sector Dynamics: Consumer staples shares gained 0.2%, while materials stocks fell by 1.4%, illustrating a divergence in market performance across sectors, which may lead investors to reassess their asset allocations.
- Earnings Highlights: Verizon Communications reported better-than-expected Q4 results, with a 2.0% year-over-year revenue growth reaching $36.40 billion, surpassing the analyst consensus of $36.06 billion, and an adjusted EPS of $1.09 exceeding the $1.05 estimate, showcasing the company's solid financial performance.
- Economic Data: U.S. producer prices increased by 0.5% month-over-month in December, marking the largest rise in three months and exceeding market expectations of 0.2%, potentially signaling increased inflationary pressures that could influence future monetary policy.
See More
VivoSim Labs Expands NAMKind Services in Asia-Pacific
- Stock Surge: VivoSim Labs, Inc. (VIVS) shares soared by 145% in overnight trading, climbing from $1.70 to $4.18, indicating strong market enthusiasm for its new distribution agreements.
- Service Expansion: The company has expanded its NAMKind human toxicology services across the Asia-Pacific region through new distributor agreements with JCBio and Tekon Biotech, aiming to accelerate the availability of liver and small intestine toxicology platforms.
- Regulatory Alignment: Korea's Ministry of Food and Drug Safety is advancing efforts to evaluate NAM methodologies, supporting the adoption of scientifically robust evidence that emphasizes human predictivity and performance, enhancing the accuracy and efficiency of toxicology research.
- Growing Market Demand: With increasing global demand for New Approach Methodologies, VivoSim's NAMKind platform is designed to deliver results within 30 days for each compound through a streamlined
See More
SanDisk Reports Strong Q2 Results, Shares Surge
- Strong Earnings Report: SanDisk's second-quarter results exceeded expectations, leading to a 20.9% surge in pre-market trading, with shares reaching $652.00, indicating strong market confidence in its financial health.
- Optimistic Q3 Guidance: The company forecasts third-quarter revenue between $4.4 billion and $4.8 billion, with non-GAAP diluted earnings per share expected to be between $12 and $14, suggesting ongoing improvement in growth potential and profitability.
- Joint Venture Extension: SanDisk announced the extension of its joint venture with Japan's Kioxia Corp. until December 31, 2034, further solidifying their strategic partnership in storage technology and enhancing market competitiveness.
- Positive Market Reaction: The significant rise in stock price reflects investor optimism about the company's future prospects, which may also attract more institutional investors, thereby elevating the company's standing in the industry.
See More
VivoSim Labs Announces $4M Public Offering Pricing
- Offering Size: VivoSim Labs announced a best-efforts public offering of up to $4 million, with an initial closing expected to raise $3 million on April 1, 2026, indicating the company's intent to leverage capital markets for growth.
- Stock Issuance Details: The initial closing will involve the issuance of 286,557 common shares at a subscription price of $1.140 per share, along with 2.34 million prefunded warrants, showcasing the company's flexible financing structure.
- Warrant Arrangement: The company will issue 3.95 million common warrants allowing the purchase of up to 150% of the common stock sold, with an exercise price of $1.710 per share, immediately exercisable and expiring in five years, enhancing potential returns for investors.
- Subsequent Financing Plans: The second closing will consist of an additional $1 million in common stock or prefunded warrants, subject to conditions like minimum closing price and average trading volume, reflecting the company's sensitivity to market dynamics and cautious financing strategy.
See More
VivoSim Plans Up to $4M Best-Efforts Public Offering
- Offering Overview: VivoSim (VIVS) plans a best-efforts public offering of up to $4 million in common stock or pre-funded warrants, along with warrants tied to an additional $15 million in shares, indicating the company's proactive approach to capital markets.
- Unit Structure Details: Each unit consists of a share or pre-funded warrant and a warrant to purchase 1.5 shares, priced at an assumed $1.69 per unit, designed to attract more investor participation in the offering.
- Anti-Dilution Protection: Common warrants are immediately exercisable, expire in five years, and include anti-dilution price protection with a $0.01 floor, providing additional security for investors and enhancing the offering's appeal.
- Phased Offering Strategy: The financing is structured in two tranches: an initial $3 million and a second tranche of $1 million, subject to stock price and liquidity conditions, demonstrating the company's sensitivity to market dynamics and ability to adapt accordingly.
See More
VivoSim Labs Expands NAMKind Services to Asia-Pacific Region
- Market Expansion: VivoSim Labs has signed agreements with JCBio and Tekon Biotech as authorized distributors for NAMKind services in Korea and China, significantly enhancing its commercial presence in the Asia-Pacific region and expected to drive market share growth in rapidly expanding markets.
- Service Innovation: The NAMKind human-based toxicology services are designed to help drug developers identify liver and gastrointestinal liabilities earlier, thereby reducing the likelihood of downstream failures and providing pharmaceutical and biotechnology companies with more efficient asset prioritization.
- Growing Demand: The company is scaling capacity to meet increasing global demand, particularly as drug developers seek earlier readouts and clearer translation to clinical outcomes, which will help reduce late-stage attrition rates.
- Sentiment Shift: Over the past 24 hours, retail sentiment around VIVS stock on Stocktwits shifted from 'bearish' to 'extremely bullish', with message volume increasing from 'normal' to 'extremely high', indicating strong investor confidence in the company's future performance.
See More
U.S. Stocks Decline in Morning Trading, Dow Jones Drops Over 100 Points
- Market Performance: U.S. stocks traded lower this morning, with the Dow Jones index dropping over 100 points, reflecting a 0.28% decline to 48,933.32, indicating weakened market sentiment that could impact investor confidence.
- Sector Dynamics: Consumer staples shares gained 0.2%, while materials stocks fell by 1.4%, illustrating a divergence in market performance across sectors, which may lead investors to reassess their asset allocations.
- Earnings Highlights: Verizon Communications reported better-than-expected Q4 results, with a 2.0% year-over-year revenue growth reaching $36.40 billion, surpassing the analyst consensus of $36.06 billion, and an adjusted EPS of $1.09 exceeding the $1.05 estimate, showcasing the company's solid financial performance.
- Economic Data: U.S. producer prices increased by 0.5% month-over-month in December, marking the largest rise in three months and exceeding market expectations of 0.2%, potentially signaling increased inflationary pressures that could influence future monetary policy.
See More
VivoSim Labs Expands NAMKind Services in Asia-Pacific
- Stock Surge: VivoSim Labs, Inc. (VIVS) shares soared by 145% in overnight trading, climbing from $1.70 to $4.18, indicating strong market enthusiasm for its new distribution agreements.
- Service Expansion: The company has expanded its NAMKind human toxicology services across the Asia-Pacific region through new distributor agreements with JCBio and Tekon Biotech, aiming to accelerate the availability of liver and small intestine toxicology platforms.
- Regulatory Alignment: Korea's Ministry of Food and Drug Safety is advancing efforts to evaluate NAM methodologies, supporting the adoption of scientifically robust evidence that emphasizes human predictivity and performance, enhancing the accuracy and efficiency of toxicology research.
- Growing Market Demand: With increasing global demand for New Approach Methodologies, VivoSim's NAMKind platform is designed to deliver results within 30 days for each compound through a streamlined
See More
SanDisk Reports Strong Q2 Results, Shares Surge
- Strong Earnings Report: SanDisk's second-quarter results exceeded expectations, leading to a 20.9% surge in pre-market trading, with shares reaching $652.00, indicating strong market confidence in its financial health.
- Optimistic Q3 Guidance: The company forecasts third-quarter revenue between $4.4 billion and $4.8 billion, with non-GAAP diluted earnings per share expected to be between $12 and $14, suggesting ongoing improvement in growth potential and profitability.
- Joint Venture Extension: SanDisk announced the extension of its joint venture with Japan's Kioxia Corp. until December 31, 2034, further solidifying their strategic partnership in storage technology and enhancing market competitiveness.
- Positive Market Reaction: The significant rise in stock price reflects investor optimism about the company's future prospects, which may also attract more institutional investors, thereby elevating the company's standing in the industry.
See More
